Amid rev­enue dip, Pfiz­er CEO Al­bert Bourla is fo­cused on 'what's nex­t'

Pfiz­er suf­fered its first quar­ter­ly rev­enue dip since its BioN­Tech-part­nered Covid vac­cine was au­tho­rized in 2020, CEO Al­bert Bourla re­vealed on Tues­day. And if that isn’t bad enough, he ex­pects patent ex­piries to cost the com­pa­ny around $17 bil­lion be­tween 2025 and 2030.

Which is why, he em­pha­sized on the Q3 call, “It’s all about what’s next.”

Bourla out­lined am­bi­tious plans to bring 19 new prod­ucts or in­di­ca­tions to mar­ket over the next year and a half.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER